How-To Guides

Brain zaps were described as brief sensations felt inside the head or brain that most respondents characterized as an electrical jolt, shock, shiver, or vibration. Some respondents also reported auditory sensations such as a swoosh, whoosh, crackle, or rattling sound, and about 10% described a momentary change in consciousness such as brief confusion, disorientation, or a "brain blinking" experience. The most common reported duration of a single brain zap was 1 second, followed by a half second, 2 seconds, and 3 seconds.

Yes. In this internet questionnaire, respondents reported brain zaps in relation to antidepressant dose reduction, missed doses, rapid weaning, gradual weaning, or sudden discontinuation, and the study found that zap onset latency differed significantly by antidepressant half-life group. Long half-life medications had longer zap onset latencies than the other groups, and medium half-life drugs also had longer latencies than short half-life medications (Kruskal-Wallis P < .0001, χ2 = 144.6), which the authors interpret as evidence linking brain zaps to antidepressant discontinuation and serotonergic mechanisms.

Brain zaps were reported after several types of antidepressant dosing changes, but abrupt changes were common. Respondents reported 909 cases after sudden discontinuation, 844 cases when they skipped a dose, 528 during rapid weaning, and 788 during gradual weaning. The authors noted that quick changes were more likely to result in discontinuation symptoms, but slow changes did not have a strong protective effect either.

Yes. A specific trigger was reported by 1,669 respondents, and eye or head movement was by far the most commonly reported trigger, named by 1,012 respondents. Another 203 respondents reported unspecified "movement," making a total of 1,215 responses that specifically, or possibly, referred to eye movement as a trigger; the authors highlight lateral eye movement as a potentially useful clue for identifying true brain zaps.

The timing varied by antidepressant half-life. Zap onset latency was significantly longer for long half-life medications such as fluoxetine and vortioxetine than for medium- or short-half-life drugs, and medium half-life drugs also had longer onset latencies than short half-life medications such as paroxetine and (des)venlafaxine (P < .0001 for both comparisons). The study does not provide a single universal onset time, but it does show that medication half-life strongly influenced when brain zaps began after the last dose.

Associated symptoms in this study often included neurologic sensations, especially vertigo. There were 647 descriptions of neurologic signs, and almost half were vertigo. Respondents also described hearing the zaps, brief disorientation or confusion, "brain rebooting" or "blinking" sensations, and in a small number of cases brief light flashes or momentary euphoria.

Often yes. About twice as many respondents said they restarted the medication as those who did not restart it (1,468 vs 779), and among those who restarted, 682 reported that it helped versus 86 who said it did not. The authors state that restarting the same antidepressant was helpful in most cases when attempted.

In this survey, switching to another serotonergic antidepressant appeared more helpful than switching to some nonserotonergic options. Among 247 people who started a different antidepressant after brain zaps began, fluoxetine was the most common second serotonergic agent and, along with (es)citalopram and (des)venlafaxine, was reported effective in about 50% of cases. Bupropion was chosen almost as frequently as fluoxetine but was reported effective by only 8% of respondents.

Brain zaps often had a meaningful negative effect on daily life in this sample. Most respondents reported a negative impact, with 17% describing the effect as "overwhelming", causing very significant interference with functioning, and about 40% each reporting either a significant or some negative effect. Only 54 respondents reported no noticeable effect, and 11 said the brain zaps were enjoyable.

Not always. At the time of completing the questionnaire, 2,103 of 2,267 respondents (93%) said they were still having brain zaps. Among those who rated change over time, about two-thirds said their condition was "as bad as ever" or worse, 436 said it had gotten a little better, and 120 said it had gotten much better; the authors conclude that symptoms diminish and disappear after a few months for most patients, but for a minority they can last years.

Many respondents said they never reported brain zaps to a professional. Of the 2,267 respondents, 1,313 said they did not report the symptoms to a professional; 897 said they did, and 615 of those told the prescriber. The article states that many non-antidepressant recommendations, including heterogeneous tests and medications such as meclizine, were barely helpful or not helpful at all.

The main limitation is that the study used an online, self-selected convenience sample, which creates a high risk of selection bias and limits quantitative interpretation. Demographic data were not collected, and only 114 valid respondents said they completed the questionnaire after consulting written records, so the reliability of individual answers could not be verified. The authors therefore emphasize trends, internal consistency, and corroboration with their earlier online study rather than making strong causal estimates from the survey alone.